D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 127 Citations 88,433 590 World Ranking 1163 National Ranking 709

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Surgery
  • Disease

Stephen B. Hanauer mainly focuses on Internal medicine, Surgery, Gastroenterology, Crohn's disease and Placebo. Internal medicine is a component of his Ulcerative colitis, Clinical trial, Inflammatory bowel disease, Adalimumab and Gastrointestinal agent studies. His Surgery research integrates issues from Vedolizumab and Adverse effect.

His studies deal with areas such as Infliximab, Certolizumab pegol, Crohn's Disease Activity Index, Azathioprine and C-reactive protein as well as Gastroenterology. The concepts of his Crohn's disease study are interwoven with issues in Severity of illness, Rheumatoid arthritis, Fistula and Dosing. He interconnects Induction chemotherapy, Clinical endpoint, Randomized controlled trial and Management of Crohn's disease in the investigation of issues within Placebo.

His most cited work include:

  • A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease (4248 citations)
  • Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (3357 citations)
  • A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. (2837 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease. His work deals with themes such as Placebo and Surgery, which intersect with Internal medicine. His Placebo research incorporates themes from Adverse effect and Clinical endpoint, Randomized controlled trial.

His research investigates the connection between Gastroenterology and topics such as Azathioprine that intersect with issues in Mercaptopurine. Stephen B. Hanauer has included themes like Adalimumab, Certolizumab pegol, Clinical trial and Immunology in his Crohn's disease study. His Ulcerative colitis research includes elements of Colonoscopy, Colorectal cancer, Colitis and Dysplasia.

He most often published in these fields:

  • Internal medicine (62.55%)
  • Gastroenterology (45.58%)
  • Crohn's disease (33.09%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (62.55%)
  • Gastroenterology (45.58%)
  • Inflammatory bowel disease (25.58%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Internal medicine, Gastroenterology, Inflammatory bowel disease, Ulcerative colitis and Crohn's disease. Stephen B. Hanauer regularly links together related areas like Placebo in his Internal medicine studies. In his study, which falls under the umbrella issue of Placebo, Infliximab is strongly linked to Surgery.

His work carried out in the field of Gastroenterology brings together such families of science as Disease activity, Pharmacokinetics, Calprotectin, Ozanimod and Colonoscopy. As part of one scientific family, Stephen B. Hanauer deals mainly with the area of Inflammatory bowel disease, narrowing it down to issues related to the Intensive care medicine, and often Thiopurine methyltransferase. The various areas that Stephen B. Hanauer examines in his Crohn's disease study include Adalimumab and Chronic abdominal pain.

Between 2015 and 2021, his most popular works were:

  • Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis (212 citations)
  • Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions (169 citations)
  • Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection (139 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

Stephen B. Hanauer mainly investigates Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology. His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Surgery. His Inflammatory bowel disease research integrates issues from Therapeutic drug monitoring, Immunology, Intensive care medicine, Radiology and Colorectal cancer.

His Ulcerative colitis research is multidisciplinary, incorporating elements of Irritable bowel syndrome, Colitis and Retrospective cohort study. The concepts of his Crohn's disease study are interwoven with issues in Post-hoc analysis, Abscess, Azathioprine and C-reactive protein. Stephen B. Hanauer combines subjects such as Pharmacokinetics, Crohn's Disease Activity Index, Placebo-controlled study, Double blind and Colonoscopy with his study of Gastroenterology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

Yasunori Ogura;Denise K. Bonen;Naohiro Inohara;Dan L. Nicolae.
Nature (2001)

5621 Citations

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Targan;Hanauer Sb;van Deventer Sj;Mayer L.
The New England Journal of Medicine (1997)

5091 Citations

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer.
The Lancet (2002)

4780 Citations

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch.
The New England Journal of Medicine (2005)

3902 Citations

Infliximab for the treatment of fistulas in patients with Crohn's disease.

D.H. Present;P.J. Rutgeerts;S.R. Targan;S.B. Hanauer.
The New England Journal of Medicine (1999)

3136 Citations

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Jean–Frédéric Colombel;William J. Sandborn;Paul Rutgeerts;Robert Enns.
Gastroenterology (2007)

2350 Citations

Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy

Simon Lichtiger;Daniel H. Present;Asher Kornbluth;Irwin Gelernt.
The New England Journal of Medicine (1994)

2246 Citations

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak.
Gastroenterology (2006)

1831 Citations

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer.
The New England Journal of Medicine (2013)

1794 Citations

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer.
The New England Journal of Medicine (2013)

1648 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Stephen B. Hanauer

William J. Sandborn

William J. Sandborn

University of California, San Diego

Publications: 456

Laurent Peyrin-Biroulet

Laurent Peyrin-Biroulet

University of Lorraine

Publications: 376

Severine Vermeire

Severine Vermeire

KU Leuven

Publications: 373

Jean-Frederic Colombel

Jean-Frederic Colombel

Icahn School of Medicine at Mount Sinai

Publications: 295

Paul Rutgeerts

Paul Rutgeerts

KU Leuven

Publications: 288

Brian G. Feagan

Brian G. Feagan

University of Western Ontario

Publications: 286

Silvio Danese

Silvio Danese

Humanitas University

Publications: 268

Stefan Schreiber

Stefan Schreiber

Kiel University

Publications: 248

Edward V. Loftus

Edward V. Loftus

Mayo Clinic

Publications: 191

Gert Van Assche

Gert Van Assche

KU Leuven

Publications: 177

Walter Reinisch

Walter Reinisch

Medical University of Vienna

Publications: 175

Gerhard Rogler

Gerhard Rogler

University of Zurich

Publications: 175

Remo Panaccione

Remo Panaccione

University of Calgary

Publications: 170

Peter L. Lakatos

Peter L. Lakatos

McGill University

Publications: 169

Markus F. Neurath

Markus F. Neurath

University of Erlangen-Nuremberg

Publications: 168

Toshifumi Hibi

Toshifumi Hibi

Kitasato University

Publications: 168

Trending Scientists

Wai Lam

Wai Lam

Chinese University of Hong Kong

Baoyong Zhang

Baoyong Zhang

Nanjing University of Science and Technology

Colomba Di Blasi

Colomba Di Blasi

University of Naples Federico II

Søren Dahl

Søren Dahl

Technical University of Denmark

Zuliang Chen

Zuliang Chen

University of Newcastle Australia

Luciano D'Adamio

Luciano D'Adamio

Rutgers, The State University of New Jersey

Tore Jahnsen

Tore Jahnsen

University of Oslo

Alex Goldfarb

Alex Goldfarb

Inozyme Pharma

Pamela Stanley

Pamela Stanley

Albert Einstein College of Medicine

Heiko Sahling

Heiko Sahling

University of Bremen

Harish C. Phuleria

Harish C. Phuleria

Indian Institute of Technology Bombay

Richard M. Vogel

Richard M. Vogel

Tufts University

Ken Lukowiak

Ken Lukowiak

University of Calgary

Jérôme Rossier

Jérôme Rossier

University of Lausanne

Michael P. O'Driscoll

Michael P. O'Driscoll

University of Waikato

Alan Connelly

Alan Connelly

Florey Institute of Neuroscience and Mental Health

Something went wrong. Please try again later.